Results 71 to 80 of about 7,662 (208)

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults

AAPS Open
Objective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe, Caroline Pollefliet   +5 more
doaj   +1 more source

Review article: Venous thromboembolism after total joint replacement [PDF]

, 2013
published_or_final_versio
Chan, PK, Chiu, PKY, Leung, KH, Ng, FY, Yan, CH   +4 more
core   +1 more source

Deciphering the Relative Contribution of CYP3A4 Versus P‐Glycoprotein for the Shared Substrate Cyclosporine—Commentary on Lown et al.

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1546-1561, June 2025.
The oral bioavailability of cyclosporine, a substrate of both CYP3A4 and P‐glycoprotein, is subject to large inter‐individual variability, which requires frequent monitoring of plasma concentrations. In 1997, the study by Lown et al. showed that—in addition to hepatic CYP3A4—the expression of P‐gp in the intestine significantly influences the ...
Ingolf Cascorbi, Richard B. Kim
wiley   +1 more source

Topical issues of the efficiency and safety of using the first direct thrombin inhibitor in real clinical practice

Неврология, нейропсихиатрия, психосоматика, 2016
A Regional Expert Council meeting was held in Moscow on August 21, 2015 to consider different aspects of the efficiency and safety of using the first direct thrombin inhibitor dabigatran etexilate in real clinical practice.
A. V. Fonyakin
doaj   +1 more source

Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities.

Critical Care Innovations, 2020
INTRODUCTION: To estimate the incidence of thromboembolic recurrence in patients whose deep vein thrombosis (DVT) during the initial and long-term anticoagulation and after its termination was treated.
Sergyi Vasyliuk, Vitaliia Atamaniuk
doaj   +1 more source

Alternative to oral dicoumarin anticoagulants:Considerations in dental care [PDF]

, 2013
Introduction: For over 50 years, vitamin K antagonists such as warfarin (Aldocumar®) and acenocoumarol (Sintrom ®) have been the gold standard for reducing the risk of cerebrovascular events.
Chaveli López, Begonya, Mingarro de León, Ana   +1 more
core   +1 more source

Direct Oral Anticoagulants Compared to Warfarin in Patients with Intermediate‐ to High‐Risk Pulmonary Embolism: A Systematic Review and Meta‐Analysis

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT Introduction Despite recent advances in clinical therapeutics in patients with venous thromboembolism, uncertainty remains regarding the optimal anticoagulation strategy in patients with intermediate‐ to high‐risk pulmonary embolism. We aimed to evaluate the direct oral anticoagulants’ effectiveness and safety compared to warfarin in patients ...
Mohamed Nabil Elshafei, Muhammad Salem, Mutasem Almistarihi, Haider Alabd, Ahmed Khalil, Mohammed Danjuma   +5 more
wiley   +1 more source

Situación actual de los nuevos anticoagulantes orales [PDF]

, 2013
For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders. Despite its clinical efficacy, vitamin-antagonists have multiple, well-known limitations, including numerous
Albarrán Severo, Beatriz, Andujar Troncoso, Giselle, Cidoncha Morcillo, Borja, García Frade, Luis Javier, González Mena, Beatriz   +4 more
core   +1 more source

A case with congenital absence of the left atrial appendage

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Congenital absence of the left atrial appendage (LAA) is an extremely rare anatomical variation with important implications for the management of atrial fibrillation (AF). Additionally, atrial natriuretic peptide (ANP) production may be compensated by the right atrial appendage (RAA) in cases of congenital LAA deficiency.
Kosuke Muto, Naomichi Tanaka, Hitoshi Mori, Yoshifumi Ikeda, Ritsushi Kato   +4 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition

Clinical Pharmacology in Drug Development, Volume 14, Issue 5, Page 368-381, May 2025.
Abstract Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies.
Hongxia Jia, T. Eric Ballard, Liming Zhang, Lawrence Cohen, Mackenzie C. Bergagnini‐Kolev, Ian E. Templeton, Hannah M. Jones, Wei Yin   +7 more
wiley   +1 more source